Sergliflozin

Drug Profile

Sergliflozin

Alternative Names: 869682; GSK 869682; GW869682X; KGT-1251

Latest Information Update: 06 Jun 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer GlaxoSmithKline
  • Class Antihyperglycaemics; Glucosides
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 06 Jun 2008 Kissei and GlaxoSmithKline extended their agreement for SGLT2 inhibitors in Japan, South Korea, China and Taiwan
  • 29 Feb 2008 Discontinued - Phase-II for Obesity in USA (PO)
  • 29 Feb 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top